Table 3. Variant combinitorials versus drug activity correlation^a.

	Drug					Cells with variant(s)		Cells without variant(s)
			Mechanism	Developmental		Have drug	No drug	Have drug	No drug
Gene name	NSC IDb	Name	of actionc	status	Response	response	response	response	response		MCCd
BRAF	761431	Vemurafenib	YK	FDA approved	Sensitivity	9	1	0		49	0.94
BRAF	354462	Hypothemycin	YK	Clinical trial	Sensitivity	9	2	6		43	0.62
BRIP1	127716	5-Aza-2′-deoxycytidine	DNMT	FDA approved	Sensitivity	3	0	4		40	0.62
DFFB	127716	5-Aza-2′-deoxycytidine	DNMT	FDA approved	Sensitivity	3	0	4		40	0.62
DNMT3B	118218	Fludarabine phoshate	Ds	FDA approved	Sensitivity	6	0	7		44	0.63
GTF3C4	36405	Chelerythrine	PKC,STK	Clinical trial	Sensitivity	3	1	1		44	0.73
HDAC10	679828	PD-98059	STK	Clinical trial	Sensitivity	6	0	8		45	0.60
HTRA2	409962	Carmustine	A7	FDA approved	Sensitivity	5	0	6		49	0.64
IDH1	719276	Fulvestrant	Ho	FDA approved	Sensitivity	3	1	2		52	0.64
IGF1R	127716	5-Aza-2′-deoxycytidine	DNMT	FDA approved	Sensitivity	3	0	4		40	0.62
IGF1R	36405	Chelerythrine	PKC,STK	Clinical trial	Sensitivity	3	0	1		45	0.86
JAK3	122758	Tretinoin	Ho	FDA approved	Sensitivity	3	0	1		55	0.86
JAK3	697979	Denileukin	IL	FDA approved	Sensitivity	3	0	2		55	0.76
MORF4L1	750690	Sunitinib malate	YK	FDA approved	Sensitivity	7	1	6		45	0.63
MUS81	105014	Cladribine	Ds	FDA approved	Sensitivity	9	1	7		42	0.64
MUS81	606869	Clofarabine	Ds	FDA approved	Sensitivity	8	0	9		42	0.62
RAD52	109724	Ifosfamide	A7	FDA approved	Sensitivity	5	1	4		41	0.63
SETD2	102816	Azacytidine	DNMT	FDA approved	Sensitivity	5	0	6		49	0.64
SLC12A8	366140	Pyrazoloacridine	Db	Clinical trial	Sensitivity	7	0	8		31	0.61
SLC17A9	365798	Fostamatinib disodium	YK	Clinical trial	Sensitivity	7	1	5		34	0.64
SLC22A16	105014	Cladribine	Ds	FDA approved	Sensitivity	10	2	6		41	0.64
SLC22A16	312887	Fludarabine phosphate	Ds	FDA approved	Sensitivity	9	3	5		43	0.61
SLC22A16	606869	Clofarabine	Ds	FDA approved	Sensitivity	10	2	7		40	0.61
STAT2	102816	Azacytidine	DNMT	FDA approved	Sensitivity	5	0	6		49	0.64
STAT2	34462	Uracil mustard	A7	FDA approved	Sensitivity	7	0	8		45	0.63
TET2	633782	Simvastatin	AM	FDA approved	Sensitivity	9	1	5		26	0.67
TNFSF11	127716	5-Aza-2′-deoxycytidine	DNMT	FDA approved	Sensitivity	3	0	4		40	0.62
UNC5B	376128	Dolastatin 10	Tu	Clinical trial	Sensitivity	8	2	5		35	0.62
ABCC10	141633	Homoharringtonine	Apo	FDA approved	Resistance	5	1	4		37	0.62
ABCC2	756645	Crizotinib	YK	Clinical trial	Resistance	8	0	9		42	0.62
CTNNA2	36405	Chelerythrine	PKC,STK	Clinical trial	Resistance	3	0	3		43	0.68
MCM2	608210	Vinorelbine tartrate	Tu	FDA approved	Resistance	3	0	4		50	0.63
POLD1	105014	Cladribine	Ds	FDA approved	Resistance	8	0	10		41	0.60
SERPINE2	38721	Mitotane	Ho	FDA approved	Resistance	3	1	0		39	0.86
SLC39A8	686288	Aminoflavone	Db	Clinical trial	Resistance	10	1	8		40	0.63
SLC4A1AP	752782	Pazopanib	YK	FDA approved	Resistance	3	0	4		46	0.63

^aInput compounds (Figure 4A and Table S3) and amino acid changing variants compared by Matthew's correlation coefficient.

^bNational Service Center identifier.

^cDrug mechanism of action abbreviations: A7 is alkylating at N-7 position of guanine; Apo is apoptotic, Db is DNA binder; DNMT is DNA methylttransferase inhibitor; Ds is DNA synthesis inhibitor; PKC is protein kinase C inhibitor; STK is serine threonine kinase; T1 is topoisomerase 1 inhibitor; T2 is topoisomerase 2 inhibitor; and YK is tyrosine kinase inhibitor.

^dMatthew's correlation coefficient.